NK3R Inhibitors
2 drugsAbout NK3R
The neurokinin-3 receptor (NK3R) is a G protein-coupled receptor (GPCR) involved in various physiological processes. As a GPCR, it modulates intracellular signaling pathways upon activation by its cognate ligand.
NK3R has emerged as a therapeutic target, evidenced by the FDA approval of two drugs, VEOZAH and LYNKUET. Currently, there is no genetic evidence directly linking NK3R to specific diseases.
Two small molecule drugs, LYNKUET (Bayer) and VEOZAH (ASTELLAS), target NK3R for other therapeutic areas. These approvals highlight the druggability of NK3R and its potential for therapeutic modulation.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Prostate Cancer with only 1 trials.
Top Drugs
ASTELLAS and Bayer are the only two companies with approved drugs targeting NK3R.
Limited competition suggests an opportunity for new entrants, but also highlights potential market entry barriers.
Drug Modality Landscape
Modalities
Routes of Administration
NK3R is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or peptides to expand the therapeutic options for NK3R.
Clinical Trials 57 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 25 | 24 | 0 | 1 | 100% |
| Phase 2 | 14 | 7 | 1 | 6 | 88% |
| Phase 3 | 15 | 13 | 0 | 2 | 100% |
| Phase 4 | 3 | 1 | 1 | 1 | 50% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved NK3R drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting NK3R. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2023 - 2025)
The first NK3R-targeting drug was approved in 2023, with the most recent approval in 2025.
Recent approvals indicate growing interest in NK3R, but further approvals may saturate the current therapeutic area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 50 clinical trials targeting NK3R.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities